MARFLOXIN 5 MG TABLETS FOR CATS AND DOGS

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

MARBOFLOXACIN

제공처:

Krka, d.d., Novo mesto

ATC 코드:

QJ01MA93

INN (International Name):

MARBOFLOXACIN

복용량:

5 Milligram

약제 형태:

Tablets

처방전 유형:

POM

치료 그룹:

Canine, Feline

치료 영역:

Marbofloxacin

치료 징후:

Antibacterial

승인 상태:

Authorised

승인 날짜:

2013-05-03

제품 특성 요약

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Marfloxin 5 mg tablets for cats and dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Tablets.
Light brownish yellow, round, biconvex, marble tablets with bevelled
edges and with possible dark and white spots,
scored on one side.
The tablets can be divided into halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cats and dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of infections caused by strains of microorganisms
susceptible to marbofloxacin.
In dogs:
skin and soft tissue infections (skinfold pyoderma, impetigo,
folliculitis, furunculosis, cellulitis);
urinary tract infections (UTI) associated or not with prostatitis or
epididymitis;
respiratory tract infections.
In cats:
skin and soft tissue infections (wounds, abscesses, phlegmons);
upper respiratory tract infections.
4.3 CONTRAINDICATIONS
Do not use in dogs aged less than 12 months, or less than 18 months
for exceptionally large breeds of dogs, such as
Great Danes, Briard, Bernese, Bouvier and Mastiffs, with a longer
growth period.
Do not use in cats aged less than 16 weeks.
Do not use in animals with known hypersensitivity to marbofloxacin or
other (fluoro)quinolones or to any of the
excipients of the product.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
A low urinary pH could have an inhibitory effect on the activity of
marbofloxacin. Pyoderma occurs mostly secondary
to an underlying disease, thus, it is advisable to determine the
underlying cause and to treat the animal accordingly.
Each tablet contains:
ACTIVE SUBSTANCE:
Marbofloxacin
5 mg
EXCIPEINTS:
For a full list of excipients, see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_